Exact Sciences Shareholders Approve Merger with Abbott, Merger to Move Forward
AI Summary1 min read
TL;DR
Exact Sciences shareholders approved the merger with Abbott Laboratories, with 67.56% voting in favor. Abbott will acquire EXAS for $105 per share, valued at $21 billion, pending regulatory approvals.
Tags
Exact SciencesAbbott Laboratoriesmergershareholdersregulatory approvals
Exact Sciences Corp. (EXAS) shareholders have approved the proposed merger with Abbott Laboratories, with 67.56% of shares represented in person or by proxy. Abbott Laboratories will acquire EXAS for $105 per share in cash, a transaction valued at approximately $21 billion. Completion of the merger remains subject to customary closing conditions, including regulatory approvals.
